Immunotherapy for neurological diseases, present and future

被引：5

作者：

Constantino Ginestal-Lopez, Ricardo ^{[1
]}

机构：

[1] Hosp Univ Fdn Jimenez Diaz UTE, Neurol Dept, Madrid, Spain

来源：

FARMACIA HOSPITALARIA | 2018年 / 42卷 / 06期

关键词：

Alzheimer disease; Autoimmune diseases; Immunotherapy; Migraine; Movement disorders; Multiple sclerosis; Neurologic disorders; Neuromyelitis optica;

D O I：

10.7399/fh.11031

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Objective: The objective of this work is to summarize the immunological treatment of neurological diseases, describing the present situation and the challenges and opportunities the future will present. Method: After topographically classifying the autoimmune neurological pathologies, a bibliographic analysis is made to present the most relevant ones regarding the available immunotherapeutic options. Likewise, new neurological entities that will be future candidates for immunotherapy are discussed. Results: There is a large number of neurological diseases with an autoimmune basis, even though their pathophysiology is, sometimes, only partially understood. Only a few randomized controlled clinical trials support the evidence of the immunotherapies with which we treat some of these diseases. This situation is rapidly changing among entities like multiple sclerosis where level 1 of evidence clinical studies are today's standard. Alzheimer's disease and migraine are two of the most prevalent conditions that are being incorporated to the group of diseases candidates for immunotherapy. Conclusions: Taking into account the rapidly growing number of immunological therapies and of neurological diseases potentially receiving them, an adequate evaluation of the impact these treatments will have on social and healthcare system grounds is necessary to reach compromises and consensus among all the professionals involved in the management of these pathologies.

引用

页码：251 / 260

页数：10

共 99 条

[1]

Otero-Romero S., Roura P., Sola J., Altimiras J., Sastre-Garriga J., Nos C., Et al., Increase in the prevalence of multiple sclerosis over a 17-year period in osona, catalonia, Spain, Mult Scler, 19, 2, pp. 245-248, (2013)

[2]

Le Page E., Veillard D., Laplaud D.A., Hamonic S., Wardi R., Lebrun C., Et al., Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): A randomised, controlled, double-blind, noninferiority trial, Lancet, 386, 9997, pp. 974-981, (2015)

[3]

Ehler J., Koball S., Sauer M., Mitzner S., Hickstein H., Benecke R., Et al., Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: A retrospective analysis of 90 patients, PLoS One, 10, 8, (2015)

[4]

Miller A.E., Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: Clinical evidence and long-term experience, Ther Adv Neurol Disord, 10, 12, pp. 381-396, (2017)

[5]

Linker R.A., Haghikia A., Dimethyl fumarate in multiple sclerosis: Latests developments, evidence and place in therapy, Ther Adv Chronic Dis., 7, 4, pp. 198-207, (2016)

[6]

Tramacere I., Del Giovane C., Salanti G., D'Amico R., Filippini G., Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network metaanalysis, Cochrane Database Syst Rev., 9

[7]

Zhang J., Shi S., Zhang Y., Luo J., Xia Y., Meng L., Et al., Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis, Cochrane Database Syst Rev., 11

[8]

Chaundry B.Z., Cohen J.A., Conway D.S., Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis, Neurotherapeutics, 14, 4, pp. 859-873, (2017)

[9]

Kappos L., Bar-Or A., Cree B.A.C., Fox R.J., Giovannoni G., Gold R., Et al., Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A doubleblind, randomised, phase 3 study, Lancet, 391, pp. 1263-1273, (2018)

[10]

Gelfand J.M., Cree B.A.C., Hauser S.L., Ocrelizumab and other CD20<sup>+</sup> B-cell-depleting therapies in multiple sclerosis, Neurotherapeutics, 14, 4, pp. 835-841, (2017)

← 1 2 3 4 5 6 7 8 9 10 →